Regenxbio Inc (RGNX)
9.18
-0.45
(-4.67%)
USD |
NASDAQ |
Nov 21, 16:00
9.26
+0.08
(+0.87%)
After-Hours: 07:48
Regenxbio Net Income (Quarterly): -59.60M for Sept. 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -59.60M |
| June 30, 2024 | -52.99M |
| March 31, 2024 | -63.33M |
| December 31, 2023 | -62.89M |
| September 30, 2023 | -61.87M |
| June 30, 2023 | -72.06M |
| March 31, 2023 | -66.68M |
| December 31, 2022 | -59.94M |
| September 30, 2022 | -75.48M |
| June 30, 2022 | -68.18M |
| March 31, 2022 | -76.72M |
| December 31, 2021 | 294.02M |
| September 30, 2021 | -58.40M |
| June 30, 2021 | -57.64M |
| March 31, 2021 | -50.14M |
| December 31, 2020 | -46.24M |
| September 30, 2020 | 8.791M |
| June 30, 2020 | -33.76M |
| March 31, 2020 | -40.04M |
| December 31, 2019 | -26.46M |
| September 30, 2019 | -34.58M |
| Date | Value |
|---|---|
| June 30, 2019 | -1.457M |
| March 31, 2019 | -32.23M |
| December 31, 2018 | 4.306M |
| September 30, 2018 | -19.20M |
| June 30, 2018 | 10.59M |
| March 31, 2018 | 104.24M |
| December 31, 2017 | -16.00M |
| September 30, 2017 | -20.71M |
| June 30, 2017 | -14.47M |
| March 31, 2017 | -21.99M |
| December 31, 2016 | -19.61M |
| September 30, 2016 | -18.15M |
| June 30, 2016 | -14.44M |
| March 31, 2016 | -10.77M |
| December 31, 2015 | -5.176M |
| September 30, 2015 | -7.332M |
| June 30, 2015 | -6.29M |
| March 31, 2015 | -4.011M |
| December 31, 2014 | -2.336M |
| September 30, 2014 | -1.793M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-76.72M
Minimum
Mar 2022
294.02M
Maximum
Dec 2021
-36.48M
Average
-59.00M
Median
Net Income (Quarterly) Benchmarks
| Catalyst Pharmaceuticals Inc | 43.88M |
| EyePoint Pharmaceuticals Inc | -29.36M |
| Cassava Sciences Inc | -27.94M |
| Vertex Pharmaceuticals Inc | 1.045B |
| Sarepta Therapeutics Inc | 33.61M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 24.20M |
| Total Expenses (Quarterly) | 86.28M |
| EPS Diluted (Quarterly) | -1.17 |
| Enterprise Value | 199.36M |
| Gross Profit Margin (Quarterly) | 48.81% |
| Profit Margin (Quarterly) | -246.3% |
| Earnings Yield | -54.68% |
| Normalized Earnings Yield | -56.81 |